The estimated Net Worth of Sylvie Gregoire is at least $2.85 Milion dollars as of 6 July 2021. Sylvie Gregoire owns over 5,000 units of Revvity stock worth over $2,581,343 and over the last 10 years he sold PKI stock worth over $0. In addition, he makes $264,976 as Independent Director at Revvity.
Sylvie has made over 2 trades of the Revvity stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 5,000 units of PKI stock worth $231,350 on 6 July 2021.
The largest trade he's ever made was exercising 5,000 units of Revvity stock on 6 July 2021 worth over $231,350. On average, Sylvie trades about 833 units every 5 days since 2015. As of 6 July 2021 he still owns at least 22,390 units of Revvity stock.
You can see the complete history of Sylvie Gregoire stock trades at the bottom of the page.
Dr. Sylvie L. Gregoire PharmD serves as Independent Director of the Company. She was a co-founder, and since 2018 has served as Executive Chair, of EIP Pharma, Inc., a privately held therapeutics company focused on central nervous system disorders. Dr. Grégoire previously served as President of the Human Genetic Therapies division of Shire plc, a public biopharmaceutical company, from 2007 to 2013, and from 2005 to 2008 she served as a director of IDM Pharma, Inc., a public biotechnology company that now operates as a subsidiary of Takeda Pharmaceuticals, including serving as its Executive Chair from August 2006 to October 2007. From 2004 to 2005, Dr. Grégoire served as President, Chief Executive Officer and Executive Member of the board of directors of GlycoFi, Inc., a private biotechnology company. Prior to that, Dr. Grégoire was employed in several key operating and regulatory affairs positions at Biogen, Inc. and Merck & Co. Dr. Grégoire currently serves on the board of Novo Nordisk A/S, as well as one privately held company, and formerly served on the board of Vifor Pharma Ltd. Dr. Grégoire holds a Pharmacy degree from Laval University and a Doctoral degree from the State University of New York at Buffalo.
As the Independent Director of Revvity, the total compensation of Sylvie Gregoire at Revvity is $264,976. There are 11 executives at Revvity getting paid more, with Dr. Prahlad R. Singh Ph.D. having the highest compensation of $4,862,149.
Sylvie Gregoire is 58, he's been the Independent Director of Revvity since 2015. There are 5 older and 15 younger executives at Revvity. The oldest executive at Revvity Inc. is Peter Barrett, 67, who is the Independent Director.
Sylvie's mailing address filed with the SEC is 940, Winter Street, Prospectville, Waltham, Middlesex County, Massachusetts, 02451, United States.
Over the last 26 years, insiders at Revvity have traded over $204,298,889 worth of Revvity stock and bought 55,200 units worth $1,110,570 . The most active insiders traders include Alexis P Michas, Gregory L Summe oraz Robert F Friel. On average, Revvity executives and independent directors trade stock every 25 days with the average trade being worth of $6,184,617. The most recent stock trade was executed by Andrew Okun on 13 April 2023, trading 2,435 units of PKI stock currently worth $332,402.
PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, the company delivers unique solutions to serve the diagnostics, life sciences, food, and applied markets. IT strategically partners with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Its dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index.
Revvity executives and other stock owners filed with the SEC include: